Available Forms: Tablets for Oral Suspension
Available Strengths: 125 mg, 250 mg, 500 mg
Reference Brands: Exjade, Jadenu (film-coated)
Category: Anemia
Deferasirox treats transfusion-related iron overload. Available as Exjade and Jadenu in multiple strengths. Suitable for global pharma B2B supply.
Quick Response Guaranteed | Verified Suppliers
Product Description:
Deferasirox is a leading oral iron chelation therapy used to manage chronic iron overload in patients receiving long-term blood transfusions, such as those with thalassemia or sickle cell disease. It is available as 125 mg, 250 mg, and 500 mg tablets for oral suspension, and 90 mg, 180 mg, and 360 mg film-coated tablets (Jadenu®). Trusted brands like Exjade and Jadenu are approved in the US and EU. Deferasirox is manufactured in GMP-certified facilities and is ideal for pharma B2B distribution, including hospitals, clinics, and global buyers. Contact us for bulk export and regulatory support.
Deferasirox is used for treating chronic iron overload in patients who require frequent blood transfusions, such as those with thalassemia or sickle cell disease.
Deferasirox is made from the active ingredient deferasirox along with inactive excipients depending on whether it is a dispersible tablet or film-coated tablet.
The trade names are Exjade and Jadenu.
Deferasirox (Exjade and Jadenu) is manufactured by Novartis Pharmaceuticals.
The generic name is deferasirox.
The brand names are Exjade and Jadenu.
Deferasirox is manufactured by Novartis in approved facilities located in the USA and Europe.
Strength: 150 mg, 300 mg
Form: Tablets
Reference Brands: Vafseo (EU/EU/UK)
Strength: 5 mg, 20 mg, 50 mg
Reference Brands: Pyrukynd (USA)
Strength: 12.5 mg, 25 mg, 50 mg, and 75 mg
Form: Tablets / Oral suspension
Reference Brands: Promacta (USA), Revolade (EU)
Strength: 1,000 IU, 2,000 IU, 4,000 IU, 10,000 IU, 40,000 IU
Form: injection (prefilled syringe)
Reference Brands: EPOGEN (USA), PROCRIT (USA)
By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under ‘Fair use.’
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Stay updated on pharma trends and marketplace opportunities.
Online · B2B Pharma · Medical Tourism · NPP